287 related articles for article (PubMed ID: 34830871)
21. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
22. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
[TBL] [Abstract][Full Text] [Related]
23. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
Bonomo P; Desideri I; Loi M; Mangoni M; Sottili M; Marrazzo L; Talamonti C; Greto D; Pallotta S; Livi L
Clin Transl Radiat Oncol; 2018 Feb; 9():42-47. PubMed ID: 29594250
[TBL] [Abstract][Full Text] [Related]
24. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
[TBL] [Abstract][Full Text] [Related]
25. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
[TBL] [Abstract][Full Text] [Related]
27. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
Front Immunol; 2022; 13():970823. PubMed ID: 36389668
[TBL] [Abstract][Full Text] [Related]
28. Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.
Burcher KM; Bloomer CH; Gavrila E; Kalada JM; Chang MJ; Gebeyehu RR; Song AH; Khoury LM; Lycan TW; Kinney R; D'Agostino R; Bunch PM; Shukla K; Triozzi P; Furdui CM; Zhang W; Porosnicu M
Ther Adv Med Oncol; 2024; 16():17588359231217959. PubMed ID: 38249330
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer.
Akbor M; Hung KF; Yang YP; Chou SJ; Tsai PH; Chien CS; Lin LT
J Chin Med Assoc; 2020 Feb; 83(2):113-116. PubMed ID: 31834023
[TBL] [Abstract][Full Text] [Related]
30. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
31. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.
Yang ES; Deutsch E; Mehmet A; Fayette J; Tao Y; Nabell L; Spencer SA; Wang XA; Spoljoric EA; Zhang W; Hynes SM; Decker RL; Lin AKB; William WN
Radiother Oncol; 2021 Apr; 157():203-209. PubMed ID: 33577866
[TBL] [Abstract][Full Text] [Related]
32. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
33. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
Shibata H; Saito S; Uppaluri R
Front Oncol; 2021; 11():727433. PubMed ID: 34552878
[TBL] [Abstract][Full Text] [Related]
35. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
Guo Y; Nakashima T; Cho BC; Lim DW; Yang MH; Lou PJ; Corry J; Lin JC; Zhu GP; Kim KH; Zhang B; Li Z; Hong RL; Ng JYS; Tan EM; Liu YP; Stylianou C; Spiteri C; Porceddu S
Oral Oncol; 2024 Jan; 148():106657. PubMed ID: 38101313
[TBL] [Abstract][Full Text] [Related]
36. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence.
Benson R; Mallick S; Julka PK; Rath GK
J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750
[TBL] [Abstract][Full Text] [Related]
37. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
39. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review.
Hayman TJ; Bhatia AK; Jethwa KR; Young MR; Park HS
Transl Cancer Res; 2021 May; 10(5):2571-2585. PubMed ID: 35116571
[TBL] [Abstract][Full Text] [Related]
40. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Dunn LA; Riaz N; Fury MG; McBride SM; Michel L; Lee NY; Sherman EJ; Baxi SS; Haque SS; Katabi N; Wong RJ; Xiao H; Ho AL; Pfister DG
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):564-570. PubMed ID: 31678634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]